Optically-based stimulation of target cells and modifications thereto

Patent metadata

Field	Value
Publication number	US-9458208-B2
Application number	US-201414184149-A
Country	US
Kind code	B2
Filing date	Feb 19, 2014
Priority date	Nov 14, 2008
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in in vivo and in vitro environments).

First claim

What is claimed is:

1. A light-responsive ion channel comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:2, wherein the ion channel exhibits an extended conducting state after exposure to a light pulse, and wherein the ion channel comprises: i) a substitution of a cysteine residue at a position corresponding to amino acid residue 123 (C123) of SEQ ID NO:2 with a serine; and ii) a substitution of an aspartic acid residue at a position corresponding to amino acid residue 151 (D151) of SEQ ID NO:2 with an alanine.

2. The light-responsive ion channel of claim 1 , wherein the light-responsive ion channel comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:2.

3. A nucleic acid comprising a nucleotide sequence encoding the light-responsive ion channel of claim 1 .

4. The nucleic acid of claim 3 , wherein the nucleic acid is an expression vector.

5. The nucleic acid of claim 4 , wherein the expression vector is a lentivirus vector.

6. The nucleic acid of claim 4 , wherein the expression vector is an adeno-associated virus vector.

7. The nucleic acid of claim 4 , wherein the expression vector is an adenovirus-based vector.

8. The nucleic acid of claim 3 , wherein the nucleotide sequence is operably linked to a control element.

9. The nucleic acid of claim 8 , wherein the control element is a promoter.

10. The nucleic acid of claim 9 , wherein the promoter is a CaMKIIα promoter.

11. The nucleic acid of claim 4 , wherein the expression vector is a herpes simplex virus-based vector.

Assignees

• Univ Leland Stanford Junior

Inventors

• Deisseroth Karl
• Yizhar Ofer
• Gunaydin Lisa
• Hegemann Peter
• Berndt Andre

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K38/16 Primary

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title

• A61N5/0601

  Apparatus for use inside the body · CPC title

• A61K36/05

  Chlorophycota or chlorophyta (green algae), e.g. Chlorella · CPC title

• C07K14/705

  Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title